Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Rein Therapeutics

14/08/2026 12:13

Rein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -28 cents.  The lone analyst forecast for the quarter was for a loss of 17 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Rein Therapeutics Inc's reported EPS for the quarter was a loss of 19 cents​.
The company reported a quarterly loss of $5.84 million.
Rein Therapeutics Inc shares had fallen by 24.3% this quarter and lost 32.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Rein Therapeutics Inc is $6.00, about 86.9% above its last closing price of $0.79
This summary was machine generated from LSEG data August 14 at 11:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Mar. 31 2026 
-0.49
-0.10
Beat
Dec. 31 2025 
-0.21
-1.09
Missed
Dec. 31 2025 
-0.21
-0.21
Met
Jun. 30 2025 
-0.22
-0.28
Missed